While there is clear recognition of commonly experienced symptoms during the menopause transition, it occurs during a time ...

Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, July 29, 2025, to ...

Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 ...

ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults. As a new generation of ...

The agony of pain on the outer side of foot Pain on the outer side of your foot can range from annoying to debilitating. When ...

When you are going through IVF, inquire with your doctor about the statistics that are of the greatest importance to your ...

Digital eye strain is more than a nuisance, it’s a stealthy saboteur of your comfort, clarity and daily performance. Here's what to do about it.

Patients with chronic spontaneous urticaria experience inadequate symptom control and significant emotional burdens despite ...

Registering is free and simple, and if you’re between the ages of 17 and 55 and in good health, you could be the match these ...

Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...

EBITDA(1) of € 496.3 million, +9.6%, margin on revenue of 37.5% Adjusted net income(2) of € 327.8 million, +8.9% Net income of € 216.1 million, -4.1% Free cash flow(4) of € 256.8 million, +€ 0.2 ...

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.